The initial analysis revealed the following: pretreatment age (HR: 1.07, 95% CI: 1.015–1.037, P = 0.014), liver cirrhosis (HR: 5.60, 95% CI: 1.947–16.103, P = 0.001), platelet level (HR: 0.98, 95% CI: 0.965–0.988, P < 0.001), HCV RNA level (HR: 0.63, 95% CI: 0.404–0.990, P = 0.045), HBV DNA ≥ 2000 IU/mL (HR: 5.98, 95% CI: 1.954–18.292, P = 0.002), 6-month post-treatment platelet level (HR: 0.98, 95% CI: 0.966–0.990, P < 0.001), γ-GT(HR:1.03, 95% CI: 1.011–1.048, P = 0.002), and alpha fetoprotein (AFP) level (HR:1.27, 95% CI: 1.138–1.414, P = 0.004). Here, AFP is linked to cirrhosis of liver.